TCRX — TScan Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1783328 ·
Last close
$0.34
Market Cap
$21.59M
52W High
$2.57
52W Low
$0.29
ADV30
991,257
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,051,000 | — | -30,493,000 | -30,359,000 | 171,452,000 | 100,156,000 | 102,433,000 |
| Mar 2026 | 982,000 | — | -29,139,000 | -28,666,000 | 201,991,000 | 128,057,000 | 105,069,000 |
| Dec 2025 | 2,567,000 | — | -23,858,000 | -22,977,000 | 228,789,000 | 152,406,000 | 105,666,000 |
| Sep 2025 | 2,511,000 | — | -37,052,000 | -35,710,000 | 262,225,000 | 169,506,000 | 118,204,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-122,012,000
Investing CF
$95,772,000
Financing CF
$189,000
CapEx
$-2,945,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.96
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-533,528,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-121,526,000
Pretax Income TTM
$-124,305,000
Interest Exp TTM
$2,779,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,111,000
EBITDA
$-115,660,000
Free Cash Flow
$-79,923,872
Enterprise Value
$12,453,473
Total Cash
$100,156,000
Total Debt
$90,893,000
Shares Out
63,502,667
Trailing EPS
$-0.90
Book Value
$1.02
ROE
-95.8%
ROA
-31.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,325,000 | -135,813,000 | -129,766,000 | 228,789,000 | 105,666,000 | 123,123,000 | -135,319,000 |
| Dec 2024 | 2,816,000 | -134,821,000 | -127,499,000 | 371,118,000 | 130,148,000 | 240,970,000 | -110,822,000 |
| Dec 2023 | 21,049,000 | -93,458,000 | -89,218,000 | 272,149,000 | 121,282,000 | 150,867,000 | -61,358,000 |
| Dec 2022 | 13,535,000 | -66,636,000 | -66,221,000 | 199,091,000 | 99,657,000 | 99,434,000 | -66,503,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ESLA | Estrella Immunopharma, Inc. | $20.92M | $0.48 | — |
| JSPR | Jasper Therapeutics, Inc. | $20.26M | $0.61 | — |
| DYAI | DYADIC INTERNATIONAL INC | $16.83M | $0.42 | — |
| BCDA | BioCardia, Inc. | $15.90M | $1.05 | — |
| CVM | CEL SCI CORP | $29.37M | $1.67 | — |
News headlines (Yahoo Finance, 1h cache)
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
2026-09-02 12:30 · Yahoo
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
2026-09-02 11:00 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
2026-08-12 12:10 · Yahoo
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 11:00 · Yahoo
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
2026-07-29 11:00 · Yahoo
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-24 11:00 · Yahoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transpl
2026-06-22 11:00 · Yahoo
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
2026-06-03 13:19 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
2026-06-02 13:57 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.